A new low melting-point polymorph of Fenofibrate prepared via talc induced heterogeneous nucleation

Pratchaya Tipduangta, Khaled Takieddin, Laszlo Fabian, Peter Belton, Sheng Qi

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)
9 Downloads (Pure)


Fenofibrate is one of the most commonly prescribed hyperlipidemia agents. Despite its high lipophilicity and ultralow aqueous solubility, most commercially available formulations use micronized crystalline fenofibrate form I, which has a low dissolution rate and poor oral bioavailability. Little is known about the crystallization of other polymorphs from supercooled amorphous fenofibrate. This study reports a new fenofibrate polymorph (form III) obtained via a controlled heterogeneous nucleation method using low quantity (1% w/w) of the generally recognized as safe (GRAS) oral pharmaceutical excipient talc. Form III has a low melting point of 50 °C, and crystallization of form I immediately occurs after the melting of form III. The microscopic, thermal, and spectroscopic characterizations of form III confirmed the distinct molecular packing difference between the new form and other known forms. The discovery of this new form will enrich the understanding of the molecular behavior of fenofibrate and bring useful insights into the role pharmaceutical excipients in selective crystallization of pharmaceutical active ingredients.
Original languageEnglish
Pages (from-to)5011–5020
Number of pages10
JournalCrystal Growth & Design
Issue number10
Early online date24 Aug 2015
Publication statusPublished - 7 Oct 2015


  • fenofibrate
  • amorphous
  • heterogeneous nucleation
  • talc
  • polymorph

Cite this